|
Pluristem to Exhibit and Present at the BIO International Convention
Monday June 16, 10:00 am ET
|
|
|
NEW YORK--(BUSINESS WIRE)--Pluristem
Therapeutics Inc. (NASDAQ:PSTI
-
News) (DAX:PJT), a bio-therapeutics company
dedicated to the commercialization of
non-personalized (allogeneic) cell therapy
products for a variety of degenerative, ischemic
and autoimmune indications, today announced that
the Company will be exhibiting and presenting at
the BIO International Convention held in San
Diego, California, June 17-20, 2008 (Booth
#1224). William R. Prather RPh, MD, Pluristem’s
Senior Vice President of Corporate Development
will present on June 18 at 1:40 PM. The title of
the presentation is “The Clinical
Application of 3D Expanded Placental-derived
Mesenchymal Stromal Cells.”
An abstract of the presentation
is as follows:
Mesenchymal stromal cells (MSCs)
have been documented to be of value in the
treatment of a variety of degenerative,
autoimmune and inflammatory conditions.
Traditionally, MSCs have been expanded using a
variety of two-dimensional (2D) techniques.
However, a recently developed three dimensional
(3D) expansion process for these cells has been
found to result in a functional and
immunological unique MSC. This talk will expand
on these properties and the medical conditions
they could potentially address.
Mr. Zami Aberman, Pluristem's
President & CEO, stated: "We are pleased we are
able to showcase Pluristem at the BIO
International Convention, present our unique,
proprietary 3D expansion process that transforms
MSCs into our PLX cells and report on the use of
these PLX cells for a variety of indications. We
will give animal trial results for PLX-PAD,
PLX-BMT, PLX-STROKE, PLX-MS and PLX-BMTBD that
suggest potential value for these products in
treating peripheral artery disease (PAD), as an
alternative to bone marrow transplantation
(BMT), in treating ischemic stroke, multiple
sclerosis (MS) and inflammatory bowel disease
(IBD).”
About Pluristem
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of non-personalized
(allogeneic) cell therapy products for the
treatment of several severe degenerative,
ischemic and autoimmune disorders. The Company
is developing a pipeline of products, stored
ready-to-use, that are derived from human
placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental mesenchymal
stromal cells (MSCs) are expanded in the
Company's proprietary PluriXTM
3D bioreactor, which imitates the natural
microstructure of bone marrow and does not
require supplemental growth factors or other
exogenous materials. Pluristem believes that the
resultant PLX (PLacental eXpanded) cells are
multi-potent and able to differentiate into a
variety of cell types. Recent evidence also
suggests their efficacy may be related to the
secretion of cytokines or other potent immune
modulators. Furthermore, PLX cells are immune
privileged and have immunomodulatory properties,
thus protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem's first product in
development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering
from peripheral artery disease (PAD). The
Company's products in development also include
PLX-BMT, targeting the global shortfall of
matched tissue for bone marrow transplantation
(BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in
umbilical cord blood; PLX-STROKE, targeting
ischemic stroke; PLX-MS, targeting Multiple
Sclerosis; and PLX-BMTBD, targeting Inflammatory
Bowel Disease (IBD), which includes Crohn’s
disease and Ulcerative Colitis.
Pluristem has offices in the USA
with research and manufacturing facilities in
Israel.
See our product animation on
YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of
the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and
federal securities laws. For example, when we
say that our animal trial results for PLX-PAD,
PLX-BMT, PLX-STROKE, PLX-MS and PLX-BMTBD suggest
potential value for these products in treating
peripheral artery disease (PAD), as an
alternative to bone marrow transplantation (BMT),
in treating ischemic stroke, multiple sclerosis
(MS) and inflammatory bowel disease (IBD), we
are using forward-looking statements. These
forward-looking statements are based on the
current expectations of the management of
Pluristem only, and are subject to a number of
factors and uncertainties that could cause
actual results to differ materially from those
described in the forward-looking statements. The
following factors, among others, could cause
actual results to differ materially from those
described in the forward-looking statements:
changes in technology and market requirements;
our technology may not be validated as we
progress further and our methods may not be
accepted by the scientific community; we may be
unable to retain or attract key employees whose
knowledge is essential to the development of our
products; unforeseen scientific difficulties may
develop with our process; results in the
laboratory may not translate to equally good
results in real surgical settings; our patents
may not be sufficient; our products may harm
recipients; changes in legislation; inability to
timely develop and introduce new technologies,
products and applications; loss of market share
and pressure on pricing resulting from
competition, which could cause the actual
results or performance of Pluristem to differ
materially from those contemplated in such
forward-looking statements. Except as otherwise
required by law, Pluristem undertakes no
obligation to publicly release any revisions to
these forward-looking statements to reflect
events or circumstances after the date hereof or
to reflect the occurrence of unanticipated
events. For a more detailed description of the
risk and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed
from time to time with the Securities and
Exchange Commission.
For more information visit our
website at
www.pluristem.com, the content of which is
not part of this press release.
Contact:Pluristem Therapeutics Inc.
William Prather RPh, MD, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
Source: Pluristem
Therapeutics Inc.
|
|
|
|
